Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023
The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.
EP: 1.Diagnosis of Myelodysplastic Syndromes (MDS)
EP: 2.Risk Stratification of Myelodysplastic Syndromes
EP: 3.First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia
EP: 4.Patient Profile 1: A 72-Year-Old Man With MDS
EP: 5.Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia
EP: 6.Patient Profile 2: A 77-Year-Old Man With MDS
EP: 7.Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia
EP: 8.ESA Treatment Selection in MDS
EP: 9.Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS
EP: 10.Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
EP: 11.IMerge: Imetelstat in Patients With Lower-Risk MDS
EP: 12.Cytopenias Following Imetelstat Treatment in Lower-Risk MDS
Now Viewing
EP: 13.Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023
EP: 14.Treatment Options and Unmet Needs in Higher-Risk MDS
EP: 15.Updates from ASH 2023 in Higher-Risk MDS
EP: 16.Takeaways from ASH 2023 in Higher-Risk MDS
EP: 17.Closing Thoughts on the MDS Treatment Landscape
Related Videos
Related Content
